Related references
Note: Only part of the references are listed.Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine
Sanaa Eissa et al.
EUROPEAN UROLOGY (2007)
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma
MJ Wallard et al.
BRITISH JOURNAL OF CANCER (2006)
HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion
MC Hsu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer
T Takeuchi et al.
CLINICAL CANCER RESEARCH (2004)
Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK
HC Chang et al.
CELLULAR SIGNALLING (2004)
Analysis of gene expression profile in gastric cancer cells stimulated with Helicobacter pylori isogenic strains
JP Yuan et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2004)
Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma
NH Cho et al.
EUROPEAN UROLOGY (2003)
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis
J Oh et al.
CELL (2001)
Share Paper
